Literature DB >> 16574930

Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury.

Jens Weise1, Raoul Sandau, Sönke Schwarting, Olaf Crome, Arne Wrede, Walter Schulz-Schaeffer, Inga Zerr, Mathias Bähr.   

Abstract

BACKGROUND AND
PURPOSE: The physiological function of cellular prion protein (PrPc) is not yet understood. Recent findings suggest that PrPc may have neuroprotective properties, and its absence increases susceptibility to neuronal injury. The purpose of this study was to elucidate the role of PrPc in ischemic brain injury in vivo.
METHODS: PrP knockout (Prnp(0/0)) and Prnp(+/+) wild-type (WT) mice were subjected to 60-minute transient or permanent focal cerebral ischemia followed by infarct volume analysis 24 hours after lesion. To identify effects of PrPc deletion on mechanisms regulating ischemic cell death, expression analysis of several proapoptotic and antiapoptotic proteins was performed at 6 and 24 hours after transient ischemia and in nonischemic controls using Western blot or immunohistochemistry.
RESULTS: Prnp(0/0) mice displayed significantly increased infarct volumes after both transient or permanent ischemia when compared with WT animals (70.2+/-23 versus 13.3+/-4 mm3; 119.8+/-24 versus 86.4+/-25 mm3). Expression of phospho-Akt (Ser473) was significantly reduced in Prnp(0/0) compared with WT animals both early after ischemia and in sham controls. Furthermore, postischemic caspase-3 activation was significantly enhanced in the basal ganglia and the parietal cortex of Prnp(0/0) mice. In contrast, expression of total Akt, Bax, and Bcl-2 did not differ between both groups.
CONCLUSIONS: These results demonstrate that PrPc deletion impairs the antiapoptotic phosphatidylinositol 3-kinase/Akt pathway by resulting in reduced postischemic phospho-Akt expression, followed by enhanced postischemic caspase-3 activation, and aggravated neuronal injury after transient and permanent cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574930     DOI: 10.1161/01.STR.0000217262.03192.d4

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  65 in total

1.  Cellular prion protein (PrP(C)) and its role in stress responses.

Authors:  Liang Zeng; Wenquan Zou; Gongxian Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 2.  New molecular insights into cellular survival and stress responses: neuroprotective role of cellular prion protein (PrPC).

Authors:  Raymond Yen-Yu Lo; Woei-Cherng Shyu; Shinn-Zong Lin; Hsiao-Jung Wang; Shun-Sheng Chen; Hung Li
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 3.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

4.  Transport of prion protein across the blood-brain barrier.

Authors:  W A Banks; Sandra M Robinson; R Diaz-Espinoza; A Urayama; C Soto
Journal:  Exp Neurol       Date:  2009-05-05       Impact factor: 5.330

5.  Stress-protective signalling of prion protein is corrupted by scrapie prions.

Authors:  Angelika S Rambold; Veronika Müller; Uri Ron; Nir Ben-Tal; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

Review 6.  Is, indeed, the prion protein a Harlequin servant of "many" masters?

Authors:  M Catia Sorgato; Caterina Peggion; Alessandro Bertoli
Journal:  Prion       Date:  2009-10-04       Impact factor: 3.931

7.  Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis.

Authors:  Shigeki Tsutsui; Jennifer N Hahn; Trina A Johnson; Zenobia Ali; Frank R Jirik
Journal:  Am J Pathol       Date:  2008-10       Impact factor: 4.307

8.  Context dependent neuroprotective properties of prion protein (PrP).

Authors:  Andrew D Steele; Zhipeng Zhou; Walker S Jackson; Chunni Zhu; Pavan Auluck; Michael A Moskowitz; Marie-Francoise Chesselet; Susan Lindquist
Journal:  Prion       Date:  2009-10-16       Impact factor: 3.931

Review 9.  Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Authors:  Erik C Gunther; Stephen M Strittmatter
Journal:  J Mol Med (Berl)       Date:  2009-12-04       Impact factor: 4.599

Review 10.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.